The UK Competition Authority fines two pharma companies £70M for overcharging the National Health Service (Pfizer / Flynn)

£70 million in fines for pharma firms that overcharged NHS* After reassessing part of the case, the CMA has found that Pfizer and Flynn abused their dominant positions to overcharge the NHS for a life-saving epilepsy drug. Pharmaceutical companies Pfizer and Flynn fined £63 million and £6.7 million respectively NHS costs for the drug rose from £2 million to £50 million in a single year CMA CEO: “These firms illegally exploited their dominant positions to charge the NHS excessive prices and make more money

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • United Kingdom’s Competition Authority - CMA (London)

Quotation

UK Competition Authority, The UK Competition Authority fines two pharma companies £70M for overcharging the National Health Service (Pfizer / Flynn), 21 July 2022, e-Competitions July 2022, Art. N° 107824

Visites 135

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues